{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:28:28Z","timestamp":1795040908463,"version":"4.10.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1996,4,1]],"date-time":"1996-04-01T00:00:00Z","timestamp":828316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1996,4,1]],"date-time":"1996-04-01T00:00:00Z","timestamp":828316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1996,4]]},"DOI":"10.1136\/ard.55.4.218","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T23:49:46Z","timestamp":1217288986000},"page":"218-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"title":["Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?"],"prefix":"10.1016","volume":"55","author":[{"given":"M.J","family":"van der Veen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J","family":"Dinant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"van Booma-Frankfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A","family":"van Albada-Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00002281-199305010-00005","article-title":"Immunopathogenesis, diagnosis, and treatment of giant cell arteritis, temporal arteritis, polymyalgia rheumatica, and Takayasu's arteritis","volume":"5","author":"B, Hellmann D.","year":"1993","unstructured":"Hellmann D B. Immunopathogenesis, diagnosis, and treatment of giant cell arteritis, temporal arteritis, polymyalgia rheumatica, and Takayasu's arteritis. Curr Opin Rheumatol 1993; 5: 25-32.","journal-title":"Curr Opin Rheumatol"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0049-0172(84)90012-X","article-title":"Long-term follow-up of polymyalgia rheumatica: evidence for synovitis","volume":"13","author":"A, Healey L.","year":"1984","unstructured":"Healey L A. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 322-8.","journal-title":"Semin Arthritis Rheum"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0954-6820.1981.tb11604.x","article-title":"Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids","volume":"209","author":"Bengtsson, B.-A.; Malmvall, B.-E.","year":"1981","unstructured":"Bengtsson B-A, Malmvall B-E. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 1981; 209: 337-45.","journal-title":"Acta Med Scand"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/ard.52.12.847","article-title":"The clinical and laboratory course of polymyalgia rheumatica\/giant cell arteritis after the first two months of treatment","volume":"52","author":"Kyle, V.; L, Hazleman B.","year":"1993","unstructured":"Kyle V, Hazleman B L. The clinical and laboratory course of polymyalgia rheumatica\/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993; 52: 847-50.","journal-title":"Ann Rheum Dis"},{"key":"ref_5","first-page":"1797","article-title":"Temporal arteritis: clinical aids to diagnosis","volume":"15","author":"Femandez-Herlihy, L.","year":"1988","unstructured":"Femandez-Herlihy L. Temporal arteritis: clinical aids to diagnosis. Rheumatol 1988; 15: 1797-801.","journal-title":"Rheumatol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.42.4.374","article-title":"Polymyalgia rheumatica and corticosteroids: how much for how long?","volume":"42","author":"R, Behn A.; T, Perera; B, Myles A.","year":"1983","unstructured":"Behn A R, Perera T, Myles A B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374-8.","journal-title":"Ann Rheum Dis"},{"key":"ref_7","first-page":"361","article-title":"Duration of corticosteroid therapy in giant cell arteritis","volume":"7","author":"Fernandez-Herlihy, L.","year":"1980","unstructured":"Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. JRheumatol 1980; 7: 361-4.","journal-title":"JRheumatol"},{"key":"ref_8","first-page":"309","article-title":"Polymyalgia rheumatica. Duration of therapy and long-term outcome","volume":"79","author":"T, Ayoub W.; M, Franklin C.; D, Toretti","year":"1985","unstructured":"Ayoub W T, Franklin C M, Toretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am JMed 1985; 79: 309-15.","journal-title":"Am JMed"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0002-8703(80)90285-9","article-title":"Giant cell (cranial) arteritis: a clinical review","volume":"100","author":"A, Huston K.; G, Hunder G.","year":"1980","unstructured":"Huston K A, Hunder G G. Giant cell (cranial) arteritis: a clinical review. Am HeartJ 1980; 100: 99-107.","journal-title":"Am HeartJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/art.1780260720","article-title":"Treatment of resistant giant cell arteritis","volume":"26","author":"A, Healey L.; R, Wilske K.","year":"1983","unstructured":"Healey L A, Wilske K R. Treatment of resistant giant cell arteritis. Arthritis Rheum 1983; 26: 930.","journal-title":"Arthritis Rheum"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bmj.300.6721.344","article-title":"Stopping steroids in polymyalgia rheumatica and giant cell arteritis. Treatment usually lasts for two to five years","volume":"300","author":"Kyle, V.; L, Hazleman B.","year":"1990","unstructured":"Kyle V, Hazleman B L. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. Treatment usually lasts for two to five years. BMJt 1990; 300: 344-5.","journal-title":"BMJt"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/ard.48.8.662","article-title":"Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects","volume":"48","author":"Kyle, V.; L, Hazleman B.","year":"1989","unstructured":"Kyle V, Hazleman B L. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6.","journal-title":"Ann Rheum Dis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(90)91659-X","article-title":"Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma","volume":"336","author":"J, Shiner R.; J, Nunn A.; K, Fan Chung; M, Geddes D.","year":"1990","unstructured":"Shiner R J, Nunn A J, Fan Chung K, Geddes D M. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336: 137-40.","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.1780370420","article-title":"Treatment of glucocorticoidresistant or relapsing Takayasu arteritis with methotrexate","volume":"37","author":"S, Hoffman G.; Y, Leavitt R.; S, Kerr G.; M, Rottem; C, Sneller M.; S, Fauci A.","year":"1994","unstructured":"Hoffman G S, Leavitt R Y, Kerr G S, Rottem M, Sneller M C, Fauci A S. Treatment of glucocorticoidresistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82.","journal-title":"Arthritis Rheum"},{"key":"ref_15","first-page":"295","article-title":"Methotrexate treatment in the management ofgiant cell arteritis","volume":"23","author":"Hemrndez-Garcia, C.; Soriano, C.; Morado, C.","year":"1994","unstructured":"Hemrndez-Garcia C, Soriano C, Morado C, et al. Methotrexate treatment in the management ofgiant cell arteritis. ScandJRheumatol 1994; 23: 295-8.","journal-title":"ScandJRheumatol"},{"key":"ref_16","first-page":"1122","article-title":"criteria for the classification of giant cell arteritis","volume":"33","author":"G, Hunder G.; A, Bloch D.; A, Michel B.","year":"1990","unstructured":"Hunder G G, Bloch D A, Michel B A, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.","journal-title":"The American College of Rheumatology"},{"key":"ref_17","first-page":"575","article-title":"Interpretation and power of a pooled index","volume":"20","author":"H, Goldsmith C.; A, Smythe H.; A, Helewa","year":"1993","unstructured":"Goldsmith C H, Smythe H A, Helewa A. Interpretation and power of a pooled index. J Rheumatol 1993; 20: 575-8.","journal-title":"J Rheumatol"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3949\/ccjm.56.3.253","article-title":"Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis","volume":"56","author":"L, Krall P.; J, Mazanec D.; S, Wilke W.","year":"1989","unstructured":"Krall P L, Mazanec D J, Wilke W S. Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis. Cleve ClinJfMed 1989; 56: 253-7.","journal-title":"Cleve ClinJfMed"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.1780240706","article-title":"The epidemiology ofgiant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications","volume":"24","author":"Bengtsson, B.-A.; Malmvall, B.-E.","year":"1981","unstructured":"Bengtsson B-A, Malmvall B-E. The epidemiology ofgiant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 1981; 24: 899-904.","journal-title":"Arthritis Rheum"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/31.2.103","article-title":"Prevention of blindness in giant cell arteritis by corticosteroid treatment","volume":"31","author":"B, Myles A.; T, Perera; G, Ridley M.","year":"1992","unstructured":"Myles A B, Perera T, Ridley M G. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992; 31: 103-5.","journal-title":"Br J Rheumatol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/ard.47.9.733","article-title":"Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients)","volume":"47","author":"Delecoeuillerie, G.; Joly, P.; Cohen de Lara, A.; B, Paolaggi J.","year":"1988","unstructured":"Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi J B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47: 733-9.","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1136\/ard.55.7.490","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[1996,7,1]],"date-time":"1996-07-01T00:00:00Z","timestamp":836179200000}},{"DOI":"10.1136\/ard.55.8.563","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[1996,8,1]],"date-time":"1996-08-01T00:00:00Z","timestamp":838857600000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724028863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724028863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.55.4.218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:41:55Z","timestamp":1737448915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724028863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["S0003496724028863"],"URL":"https:\/\/doi.org\/10.1136\/ard.55.4.218","relation":{"erratum":[{"id-type":"doi","id":"10.1136\/ard.55.7.490","asserted-by":"object"},{"id-type":"doi","id":"10.1136\/ard.55.8.563","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[1996,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.55.4.218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1996 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}